William Blair Expects Lower Earnings for Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Research analysts at William Blair lowered their FY2025 earnings per share (EPS) estimates for Zealand Pharma A/S in a research report issued to clients and investors on Monday, July 14th. William Blair analyst A. Hsieh now anticipates that the company will earn $14.05 per share for the year, down from their prior forecast of $15.22. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.

A number of other research analysts have also recently commented on the company. BNP Paribas upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. One equities research analyst has rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Strong Buy".

Zealand Pharma A/S Trading Down 1.4%

Shares of ZLDPF traded down $0.78 during mid-day trading on Wednesday, reaching $55.77. The stock had a trading volume of 589 shares, compared to its average volume of 306. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The business's fifty day moving average is $62.75 and its 200 day moving average is $77.70. Zealand Pharma A/S has a 52-week low of $54.95 and a 52-week high of $141.74. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of -22.40 and a beta of 0.68.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.